Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the superiority of at least 1 dose of
intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an
electrophysiology (EP) laboratory.